We studied loss of heterozygosity (LOH) on the long arm of human chromosome 18 in prostate cancer to determine the location of a putative tumor suppressor gene (TSG) and to correlate these losses with the pathological grade and stage of the cancer. Of 48 specimens analysed 17 (35.4%) lost at least one allele on chromosome 18q. All the specimens with allelic losses lost at least one allele within chromosomal region 18q21. Allelic losses picked at D18S51 (19%) and D18S858 (17%). A 0.58 cM DNA segment that includes the D18S858 locus and is¯anked by the microsatellite loci D18S41 and D18S381, was lost in eight (47%) of 17 specimens with allelic losses. This segment was designated as a LOH cluster region 1 (LCR 1). Although Smad2 resides within LCR 1, it was not mutated in any of the six prostate cell lines (®ve prostate cancer cell lines and one immortalized prostate epithelial cell line) analysed, suggesting that it is not a candidate TSG in prostate cancer. A second LCR at 18q21, LCR 2, includes the D18S51 locus and is¯anked by the D18S1109 and D18S68 loci, which are separated by 7.64 cM. LCR 2 was lost in six (35%) of the 17 specimens with chromosome 18q losses. These results suggest that chromosome 18q21 may harbor two candidate prostate cancer TSGs. The candidate TSGs DCC and Smad4 are located centromeric to the LCRs. No alleles were lost within or in close proximity to these genes, suggesting that they are not targets for inactivation by allelic losses in prostate cancer. Although there was no obvious correlation between chromosome 18q LOH and the pathological grade or stage, three (37.5%) of eight low-grade cancers and nine (32.1%) of 28 organcon®ned cancers lost alleles at 18q21, suggesting that allelic losses are relatively early events in the development of invasive prostate cancer. Oncogene (2001) 20, 2273 ± 2280.
Introduction
Prostate cancer (PC) is the most common malignancy other than super®cial skin cancer and the second leading cause of cancer death in American men. It is believed that PC like other neoplastic diseases, develops and progresses through an accumulation of genetic alterations. The exact molecular mechanisms underlying the onset and progression of PC are unknown. However, the most frequently detected genetic alteration in PC is loss of heterozygosity (LOH) in speci®c chromosomal regions (Carter et al., 1990; Bova et al., 1993; Latil et al., 1994; Zenklusen et al., 1994; Gao et al., 1995; Kagan et al., 1995; Visakorpi et al., 1995; Conney et al., 1996; Ittmann, 1996; Yin et al., 1999) . Chromosomal regions with frequent allelic losses are believed to be sites of a tumor suppressor gene (TSG) that became inactivated during tumor development and/or progression. TSG can be inactivated through various mechanisms, including allelic loss and mutational inactivation of the other copy (Weinberg, 1991) . Identi®cation of TSGs within regions that show frequent allelic losses and deletions is critical in determining the multistep process of malignant transformation. Furthermore, an inactivated/mutated TSG gene might serve as a diagnostic and/or prognostic marker and as a potential target for therapy.
In PC, allelic losses were most frequently detected on chromosomes 7q, 8p, 10q, 13q, 16q and 18q (Carter et al., 1990; Bergerheim et al., 1991; Kunimi et al., 1991; Bova et al., 1993; Latil et al., 1994; MacGrogan et al., 1994; Trapman et al.,1994; Zenklusen et al., 1994; Kagan et al., 1995; Macoska et al., 1995; Suzuki et al., 1995; Visakorpi et al., 1995; Cooney et al., 1996; Cunningham et al., 1996; Li et al., 1998; Yin et al., 1999) . However, no candidate TSGs have been cloned, except for the chromosome 10q23 gene, MMAC1/ PTEN (a candidate TSG in a fraction of very advanced PCs) (Suzuki et al., 1995; Cairns et al., 1997; Li et al., 1997; Steck et al., 1997; Teng et al., 1997) . Genetic alterations in known TSGs, such as the p53, RB, and BRCA2 are rare events in PC (Brooks et al., 1996; Mottaz et al., 1997; Salem et al., 1997) . Inactivation of p53 in PC is a late event frequently associated with advanced-stage and metastatic cancer, and with the transition from androgen-dependent to androgenindependent cancer (Navone et al., 1993) . The TSG RB, which resides on chromosome 13q14, is another important TSG that plays an important role in the tumorigenesis of a variety of epithelial tumors. However, recent studies strongly suggest that RB is not a major target for inactivation in PC (Cooney et al., 1996; Melamed et al., 1997; Yin et al., 1999) . Neither is the TSG BRCA2, which resides on chromosome 13q11-12 Cooney et al., 1996; Li et al., 1998; Yin et al., 1999) .
Allelic losses on chromosome 18q are frequent events in variety of carcinomas, including colorectal (Vogelstein et al., 1988; Uchino et al., 1992; Hahn et al., 1996) , breast (Cropp et al., 1990; Devilee et al., 1991) , ovarian (Chenevix-Trench et al., 1992) , lung (Shiseki et al., 1994) , and pancreatic (Hahn et al., 1995) . A comparative genomic hybridization (CGH) study in PC reported loss of chromosome 18q regions in *19% of the cancers tested (Visakorpi et al., 1995) . LOH on chromosome 18q was reported with variable frequency (17 ± 45%) in a limited number of studies of PC (Crundwell et al., 1996; Cunningham et al., 1996; Ueda et al., 1997; Jenkins et al., 1998; Latil et al., 1999) . Although the reported frequency of allelic losses diered from study to study, 18q21 was the commonly reported region with allelic losses. This chromosomal region harbors three candidate TSGs: DCC, Smad4/DPC4 and Smad2/MADR2/JV18-1 (Fearon et al., 1990; Eppert et al., 1996; Hahn et al., 1996; Riggins et al., 1996; Thiagalingam et al., 1996) . Two of these genes, Smad2 and Smad4, are essential components in the signaling pathways of serine/threonine kinase receptors for the transforming growth factor beta (TGFb) superfamily (Eppert et al., 1996; Kong et al., 1997) .
In the present study, we attempted to re®ne the location of a chromosome 18q PC TSGs and to correlate allelic losses with the pathological grade and stage of the disease. We analysed 48 PC specimens for LOH in 17 microsatellite loci spanning the entire long arm of chromosome 18. We also searched PC cell lines and an immortalized prostate epithelial cell line for inactivating mutations in the candidate TSG Smad2.
Results
Forty-eight tumor specimens derived from 47 patients were subjected to analysis of LOH in 17 microsatellite loci on chromosome 18q (Figure 1 ). In 17 (35.4%) of the 48 primary PCs, LOH occurred in at least one locus of chromosome 18q. All the specimens that lost one or more alleles had at least one allelic loss within chromosomal band 18q21. Figure 2 shows some of these allelic losses. The frequency of allelic losses picked in two separate loci, D18S51 (19%) and D18S858 (17%), which are separated by 10.6 cM (distances according to UK Linkage Database, LDB, 26 November, 1998 update, and Collins et al., 1996) . The 0.58 cM DNA segment that is¯anked by microsatellite markers D18S41 and D18S381 and includes the D18S858 locus was lost in eight (47%) of the 17 specimens with chromosome 18q allelic losses and was designated as LOH cluster region 1 (LCR 1). The 7.64 cM DNA segment that is¯anked by the microsatellite markers D18S1109 and D18S68 and includes the D18S51 locus was lost in six (35%) of the 17 specimens with chromosome 18q allelic losses and was designated as LCR 2 (Figure 3) . Both of the LCRs are located within chromosomal band 18q21. The probability that two or more allelic losses in a PC specimen occurred within an LCR by independent events is very low, so such a series of LOH in contiguous markers was more likely due to deletion of the entire segment. In the majority of the PC specimens with LOH, these deletions were interstitial. Interestingly, of the 17 PCs with allelic losses 5 (29%) lost at least one allele within each LCR another ®ve (29%) within LCR 1 but not LCR 2, and another ®ve (29%) within LCR 2 but not LCR 1. Of the 17 PCs No alleles were lost at the candidate TSG DCC locus, which is located 3 cM centromeric to D18S858. Also, no alleles were lost in close proximity to the candidate TSG Smad4, which is located 1 cM centromeric to DCC ( Figure 3 shows the frequency of LOH in markers D18S57 and DCC). These candidate TSGs are located ousted the LCRs and are not inactivated by allelic losses in PC.
In contrast to these two genes, the Samd2 gene is located within LCR 1 (2 cM telomeric to D18S858). Figure 4 shows the physical map of the LCR 1, based on the Whitehead Institute Yeast Arti®cial Chromosome (YAC) contig. LCR 1 spans *1 Mbp of DNA. Currently, except for the candidate TSG Smad2, there are no known genes within LCR 1. To further investigate the potential of Smad2 as a candidate TSG, we sought ®rst to determine whether this gene is inactivated by mutations in ®ve prostate cancer cell lines (LNCaP, PC3, DU145, TSUPR1 and JCA1) and in the immortalized prostate epithelial cell line PNTA1 (Degeorges et al., 1995) . For this purpose we reverse transcribed (RT) the mRNA into cDNA and PCRampli®ed three overlapping cDNA fragments that span amino acids 3 ± 467. Sequence analysis of the ampli®ed cDNA fragments from these cell lines failed to identify a mutation in any of the Smad2 cDNAs.
Correlation of LOH with pathological data
LOH was detected in 35% of the high-grade (Gleason score 57) PCs and in 37.5% of the low-grade (Gleason score 46) PCs (Table 1 ). There was no statistically signi®cant correlation between chromosome 18q LOH and Gleason score 46 or Gleason score 57, (w 2 test, P=0.89). LOH was detected in 32.1% (9/28) of the organ-con®ned tumors, in 54.5% (6/11) of the tumors with extraprostatic extension, and in 25% (2/8) of the tumors with seminal vesicle involvement (Table 1) . There was no correlation between LOH and organ-con®ned PCs as compared to cancers in more advanced pathological stage cancers (P=0.57, w 2 test). However, allelic losses on chromosome 18q21 are relatively early events in the development of PC and are detected in 37.5% of the low-grade (Gleason score 46) and in 32.1% of the organ-con®ned cancers (Table 1) . Although LCR 1 and LCR 2 are suspected to house TSGs, there was no correlation between allelic losses in one or both regions and any pathological grade or stage. 
Discussion
Frequent loss of alleles at a speci®c chromosomal region is highly associated with the inactivation of a TSG (Weinberg, 1991) . Frequent LOH on the long arm of chromosome 18 was detected in a variety of cancers and was previously reported to cluster within chromosomal band, 18q21 (Vogelstein et al., 1988; Huang et al., 1992; Cliby et al., 1993; Brewster et al., 1994; Shibagaki et al., 1994; Hahn et al., 1995; Takita et al., 1995) . This chromosomal band harbors the candidate TSGs DDC, Smad4, and Samd2 (Fearon et Hahn et al., 1996; Eppert et al., 1996; Riggins et al., 1996) . Previous CGH and LOH studies of PC indicated frequent deletion of 18q21 chromosomal band (Gao et al., 1993; Visakorpi et al., 1995; Crundwell et al., 1996; Ueda et al., 1997) . Our data further de®ne the areas of allelic losses within 18q21 chromosomal region by identifying two LCRs within the chromosomal band. LCR 1 was limited to a relatively small region (*1 Mbp of DNA)¯anked by microsatellite loci D18S41 and D18S381 (Figure 3 and 4). LCR 2 was limited to a *7.6-cM region,¯anked by microsatellite loci D18S1109 and D18S68 (Figure 3 ). These LCRs are likely to harbor the candidate PC TSGs. Previous studies detected a variable range (11 ± 45%) of LOH at the DCC locus (Gao et al., 1993; Crundwell et al., 1996; Ueda et al 1997) . In none of these studies DCC was inactivated by mutations or small deletions in exonic sequences (Gao et al., 1993; Crundwell et al., 1996; Ueda et al 1997) ; Thus, the involvement of DCC in PC was constantly questioned. In part, the reason for diculties in detecting mutations at the DCC locus might be technical. DCC is an extremely large gene with at least 29 exons, which are spread over 1.35 Mbp of DNA ; it is dicult to scan such a large gene for inactivating mutations. The DCC cDNA is also large, predicting a 1447-amino acid transmembrane protein, that comprises four immunoglobulinlike and six ®bronectin Type III-like domains showing a high homology to the neural cell adhesion molecule family of cell surface proteins Reale et al., 1994) . Other laboratories suggested that DCC may only play a limited role in the late stages of PC progression (Brewster et al., 1994; Crundwell et al., 1996) . However, in contrast to these reports, our data indicate that DCC and Smad4 are located outside the LCRs. In addition, no alleles were lost within or in close proximity to these loci, strongly suggesting that neither DCC nor Smad4 is a candidate TSG in PC. The dierences between our results and those of previous studies might be due to variations among PC specimens analysed. However, since we did not test PC metastasis, it is still possible that DCC is the target for inactivation by allelic losses in metastatic PC, as suggested by Ueda et al. (1997) . Nevertheless, in the present study DCC was not inactivated by allelic losses even in advanced PCs with seminal vesicle invasion, suggesting that DCC plays a very limited role in progression to invasive PC.
Smad4 and Smad2 are key components of the signaling pathways of serine/threonine kinase receptors for TGF-b. Inactivation of Smad4 and/or Smad2 can result in disruption of the signal transduction pathway between cell membrane receptors for the TGF-b cytokine family and the cell nucleus. Because many cancers of epithelial origin and hemopoietic origin develop resistance to the regulatory eects of TGF-b, it has been postulated that functional inactivation of intracellular eectors, such as Smad4 and Smad2, is responsible for this resistance that contributes to development of a tumorigenic phenotype in a wide variety of cancers (Alexandrow and Moses, 1995) . Alterations in Smad4 were detected in *50% of all pancreatic carcinomas (Goggins et al., 1998) , and in *20% of colorectal carcinomas (Thiagalingam et al., 1996; Hahn et al., 1998) , but are uncommon in other cancers, including prostate Nagatake et al., 1996; Schutte et al., 1996; MacGrogan et al., 1997) . In our study, no alleles were lost in close proximity to the Smad4 locus, at D18S57, supporting the previous observation that Smad4 is not a target for inactivation in PC (MacGrogan et al., 1997) . Furthermore, our data indicate that Smad4 is located outside the LCRs. Overall, our data suggest that neither DCC nor Smad4 is a candidate TSG in PC.
Mutations in Smad2 have been found in a subset of colorectal and lung cancers (Eppert et al., 1996; Riggins et al., 1996; Uchida et al., 1996) . In the present study Smad2 was located within the 0.58 cM region designated LCR 1 (Figures 3 and 4) . These data supported the hypothesis that Smad2 might be a strong candidate for a PC TSG. However, sequence analysis of the Smad2 coding region in ®ve PC cell lines and in an immortalized prostate epithelial cell line failed to identify mutations. Since most of the PC cell lines were established from metastatic PCs, and are thus expected to display more genetic alterations than do primary PCs, these results, in addition to a recent study by Latil et al. (1999) that failed to identify Smad2 mutations in primary and metastatic PCs, suggest that Smad2 is not a candidate TSG in PC. LCR 1 is a relatively small (*1 Mbp) region that may house a limited number of genes (*10, assuming 100 Kbp/gene). According to the current genomic databases (http:www.ncbi.nlm.-nih.gov.) there are 10 ESTs within LCR1, three of them are expressed in the prostate epithelium (Hs10881, Hs25674, Hs26). However, additional studies will be necessary to identify, and examine each of these genes as a potential TSG in PC.
The present study identi®ed second LCR at 18q21, LCR 2, suggesting that there might be a second TSG within the same chromosomal band. This large (7.65 cM) region may include many genes. According to the current update of the genomic databases, LCR2 includes at least eight known genes (PAI2, bcl-2, LMAN1, GRP, SCCA1, SCCA2, MaspinI and HeadpinI) and 29 ESTs. Eight of the ESTs (Hs45107, Hs96, Hs5822, Hs12017, Hs10878, Hs23542, Hs18800, and Hs74050) are expressed in prostate epithelium. To pin point the location of a candidate TSG within LCR2, additional eorts must be made to limit this region.
In contrast to a report of signi®cant correlation between LOH on band 18q21 and clinical stage, especially in metastasis (Ueda et al., 1997) , our study revealed no signi®cant correlations between LOH and pathological data (see also Table 1 ). On the contrary, our results suggest that inactivation of the 18q21 candidate TSG/s is not associated with the dierentiation stage of PC. However, our ®nding that 37.5% of dierentiated PCs (Gleason score 46) lost alleles suggests that allelic losses are relatively early events in the development of invasive PC. Additional eorts will be necessary to identify and clone the PC candidate TSGs of chromosomal band 18q21.
Materials and methods

PC specimens
Forty-eight archival, formalin-®xed paran embedded, PC specimens derived from 47 patients who had undergone radical prostatectomy at The University of Texas M.D. Anderson Cancer Center were selected for the study. A hematoxylin-and-eosin-stained section from each of the selected blocks was used to map the areas of tumor and normal tissue. The corresponding areas were scraped from unstained sections (eight sections of 8 mm) using a scalpel. A control DNA was also extracted from blood leukocytes of most of the selected patients. Within the same patient there was no dierence in heterozygosity between DNA extracted from histologically normal prostatic tissue adjacent to the cancer focus from an archival specimen, and the DNA from blood leukocytes. Tumor specimens were graded according to the Gleason system (Table 1) (Gleason, 1977) . The primary tumors included 28 organ-con®ned (pT 2 N 0 M 0 ) PCs, 11 locally advanced PCs with extraprostatic extension (pT 3 aN 0 M 0 ), eight PCs with seminal vesicle involvement (pT 3b N 0 M 0 ) and one primary tumor with metastasis to regional lymph node (pT 3a N 1 M 0 ) (Table 1) (classi®cation according to Fleming et al., 1997) .
DNA extraction
DNA extraction from paran-embedded specimens was performed as follows: Each paran-blocked specimen was serially sectioned into eight 8-mm sections, which were applied individually to glass slides. The ®rst slide of each specimen was stained with hematoxylin and eosin to visualize areas of stroma and low-and high-grade carcinomas. Cancerous areas were circumscribed with ink. Areas corresponding to the cancer focus and the normal adjacent prostate epithelium were scraped from the unstained slides with a sterile scalpel blade into respective plastic Eppendorf tubes. Deparanization was performed by twice adding 400 ml of xylene, and incubating the tube for 1 h at 558C. The specimens were washed three times with ethanol (100, 95 and 100%) and airdried. Next, 500 ml of a lysis buer (100 mM NaCl, 10 mM Tris-HCl, pH 7.5, 100 mM EDTA, 0.5% SDS, 1 mg/ml proteinase K) was added, and the specimens were incubated overnight at 508C. The DNA was phenol/chloroformextracted and ethanol precipitated using 20 mg glycogen as a carrier. The DNA pellet was washed once with 70% ethanol and once with 100% ethanol, dried and resuspended in 100 ml of water.
PCR amplification of microsatellite sequences
Primers for microsatellite sequences were obtained from Research Genetics (Huntsville, AL, USA) and are listed in Figure 1 . PCR ampli®cation was carried out as described in detail (Kagan et al., 1995) .
Analysis of LOH
Normal DNA samples (from archival material, tip of seminal vesicle or leukocytes), that were heterozygous at a given locus (i.e., having two alleles of a microsatellite locus of dierent sizes) were considered`informative', whereas homozygous samples were considered`noninformative'. The signal intensity of 32 P-labeled, PCR-ampli®ed microsatellite alleles were determined from X-ray ®lm autoradiography (X-Omat; Kodak, Rochester, NY, USA), by densitometry (Pharmacia Biotech, Uppsala, Sweden), and/or by visual examination (three independent observers). LOH was considered to have occurred if an entire allele was absent, or if the intensity of one of the two alleles in the tumor DNA was less than 50% of that in corresponding normal-tissue DNA, for a given amount of DNA. Although PCR ampli®cation cannot be considered quantitative, we optimized the PCR conditions so that equal amounts of template should have produced equal amounts of ampli®ed product. We performed 27 ampli®ca-tion cycles, which we demonstrated to be in the linear part of the ampli®cation process (i.e., before product saturation; data not shown). We also conducted a series of titrations with dierent proportion of homozygous and heterozygous templates to assess the in¯uence of normal tissue`contamination' in our PCR ampli®ed tumor samples. We determined that we could detect as little as 30%`contamination' by heterozygous template in homozygous DNA (data not shown). Thus, our limit of 50% intensity for LOH is very conservative. Results of LOH were repeated at least three times.
Microsatellite sequences and genetic maps
Microsatellite sequences and the heterozygosity of each marker were obtained from the genome database at http:// www.gdb.org/. Chromosomal maps and distances were obtained from the LDB at http://cedar.genetics.soton.ac.uk/ pub/chrom18/map (updated 26 November, 1998; Collins et al., 1996) and Genethon (Dib et al., 1996) . Some of the YAC contig data was obtained from http://www.genome.wi.edu/ cgibin/contig/lookup_contig. The search for candidate genes and ESTs located within LCR1 and LCR2 was assisted by Genomic and Genetic Resources on the World Wide Web at http://www.ncbi.nlm.nih.gov/.
Statistical analysis
The normality of the percentage of LOH distribution was tested using the Kolmogorov-Smirnov continuous cumulative distribution test (Zar, 1991) . The signi®cance of allelic losses was correlated with pathological stage and Gleason score, using the w 2 test essentially as described previously (Kagan et al., 1995) .
RNA extraction, RT ± PCR amplification of the Smad2 coding region, and mutation screening Total RNA was extracted from the ®ve PC cell lines (LNCaP, PC3, TSUPR1, JCA1 and DU145) and from the prostate epithelial immortalized cell line (PNT1A) using Trizol reagent (Life Technologies, Inc.) according to the manufacturer's protocol. For RT ± PCR, 1 ± 5 mg of total RNA was subjected to reversed transcription with 50 ng random hexamer, in the presence of 0.5 mM of each of the four dNTPs, 200 units of Superscript II RNase H 7 reverse transcriptase (Life Technologies, Inc.) in total volume of 20 ml. Two ml of the ®rst strand cDNA was used as a template for PCR ampli®cation of the Smad2 coding region. Three overlapping cDNA fragments were ampli®ed in three separate tubes. Fragment 1 (708 bp) was ampli®ed between the forward primer, F-1 (5'-TTT CCT AGC GTG GCT TGC-3' starting at nucleotide 66), and the reverse primer, R-1 (5'-CAG GCG GTG GCG TTT CTG-3' starting at nucleotide 773). Fragment 2 (653 bp) was ampli®ed between the forward primer, F-2 (5'-TCC CAG CAG GAA TTG AGC-3' starting at nucleotide 726), and the reverse primer, R-2 (5'-CC CCA CCC TTT CAC AAA-3' starting at nucleotide 1378). Fragment 3 (577 bp) was ampli®ed between the forward primer F-3 (5'-TTT GTG AAA GGG TGG GGA-3' starting at nucleotide 1351), and the reverse primer, R-3 (5'-TCA AGA AGC AGA GCA CAC-3' starting at nucleotide 1927). Sequences were obtained from the UniGene accession number Hs.82483 and were described previously (Zhang et al., 1996) . The three overlapping fragments span almost the entire coding region (amino acids 3 ± 467). In each case, as a control for successful reverse transcription of the RNA, we reverse transcribed and PCR-ampli®ed a 626-bp b-actin cDNA fragment that does not amplify the b-actin pseudogene. For this purpose we used the following previously described primers: b-F forward primer, (5'-CCTCGCCTTTGCCGATCC-3') and b-R reverse primer, (5'-GGATCTTCATGAGGTAGTCAGTC-3') (Ra et al., 1997) . PCR ampli®cation of the reverse-transcribed products was performed in 50 ml of 20 mM Tris-HCl pH 8.4, 50 mM KCl, 1.5 mM MgCl 2 , 200 mM of each of the four dNTPs, 50 pmole of each primer (forward and reverse) and 2.5 units of Taq DNA polymerase (Life Technologies, Inc.). PCR ampli®cation included an initial DNA denaturing step (3 min at 958C), followed by 30 cycles of PCR ampli®cation consisting of the following steps: DNA denaturing (1 min at 948C), primer annealing (1 min at 508C) and primer extension (3 min at 728C). The ®nal step in the PCR ampli®cation consisted of primer extension (10 min at 728C). Mutation screening was carried out by direct autosequencing of PCR-ampli®ed Smad2 cDNA fragments 1, 2 and 3.
